Background: The term Metabolic-Associated Fatty Liver Disease (MAFLD), introduced in 2020, replaces Non-Alcoholic Fatty Liver Disease (NAFLD) to better reflect liver fat buildup linked to metabolic disorders, including those with a history of alcohol use. MAFLD is often associated with coagulation issues due to liver dysfunction, which can disrupt the balance of blood clotting factors. This study aims to determine the association between MAFLD fibrosis severity and coagulation disorders. Methods: This cross-sectional study at Dr. Wahidin Sudirohusodo Central General Hospital involved 140 subjects with MAFLD aged > 18 years, with sequential sampling. coagulations factor examination through blood samples with patient consent. Mann Whitney test was used for statistical analysis. Results: This study involved 140 subjects, with a mean age of 49.6 ± 9.7 years. Obesity was observed in 106 participants (75.7%), hypertension in 42 participants (30%), elevated triglycerides (>150 mg/dL) in 110 participants (78.6%), and diabetes in 41 participants (29.3%). MAFLD severity was categorized as F1 in 53 participants (37.9%) and F2 in 87 (62.1%). This study found that patients with significant fibrosis (F2) had an extended Prothrombin Time (PT), lower platelet count, and higher D-dimer levels compared to patients with mild fibrosis (F1) (all P<0.05). Specifically, PT was 21.8 seconds in F2 compared to 13.3 seconds in F1, platelet count was 185 x 10³/µL in F2 compared to 221 x 10³/µL in F1, and D-dimer level was 1.85 µg/mL in F2 compared to 1.5 µg/mL in F1. Conclusion: This study highlights a relationship between the severity of MAFLD fibrosis and changes in coagulation profiles, emphasizing the impact on PT, platelet counts, and D-dimer levels.